SEC Form 4 · accession 0001127602-17-002252
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alane P Barnes
Officer — VP, General Counsel & Corp Sec
Period of report
Jan 20, 2017
Accepted (ET)
Jan 24, 2017 · 9:28 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 20, 2017 | F | 2,599 | $5.95 | D | 75,497 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014.